Global Iohexol API Market Strategic Research Report

Scope of the Report

The global Iohexol API market size is predicted to grow from US$ 739 million in 2025 to US$ 1,162 million in 2032; it is expected to grow at a CAGR of 6.7% from 2026 to 2032.

Iohexol is a non-ionic, iodinated radiocontrast agent used to enhance visibility of anatomical structures in X-ray based imaging procedures (CT, angiography, myelography, urography, joint studies and other contrast-enhanced scans). The active pharmaceutical ingredient (API) — chemically an organoiodine compound — is supplied to formulators of finished contrast media (sterile injectable solutions, oral/rectal solutions for bowel studies, or intrathecal preparations) and, in some cases, to manufacturers of specialty laboratory reagents that use iodinated density media. In commercial terms the “Iohexol API market” therefore covers: production and sale of technical- and pharmaceutical-grade Iohexol (including batches certified to pharmacopeial standards); regulatory documentation such as Drug Master Files (DMFs) and certificates of analysis supplied to finished product manufacturers; contract manufacturing (CMO) and custom synthesis for brand and generic contrast media producers; and the downstream finished-dosage contrast media market that ultimately consumes the API.

Iohexol API sold into the pharmaceutical channel must meet stringent purity, identity, and particulate/sterility standards appropriate for parenteral use; producers commonly supply documentation aligned with pharmacopeial monographs and regulatory expectations for injectable contrast media. Because finished contrast products are administered intravenously, intrathecally, or orally for diagnostic imaging, the API’s manufacturing process, residual solvent profile, heavy-metal content, and impurity profile are central to market acceptability. Compliance with pharmacopeial monographs and the ability to support regulatory filings (e.g., provision of a US DMF, CEP for EU markets, or equivalent dossiers) are usual entry barriers for suppliers.

In 2024, global Iohexol API production reached approximately 5,545.5 MT, with an average global market price of around US$ 121.5 per kg. The global single-line production capacity ranges from 500 to 800 MT per year. The industry's gross profit margin is approximately 35%-45%.

Demand for Iohexol API is driven by the global use of contrast-enhanced imaging in hospitals, outpatient imaging centers, interventional radiology, cardiology suites, and surgical planning. The primary use is in computed tomography (CT) angiography and general CT imaging to delineate blood vessels, organs, and lesions; it is also used in intrathecal myelography and specialized procedures. Growth drivers on the demand side typically include expansion of medical imaging capacity (new CT installations and interventional suites), ageing populations with higher imaging utilization, rising incidence and detection of chronic diseases (cardiovascular disease, cancer), and broader adoption of minimally invasive image-guided procedures that require high-quality contrast agents. In many clinical pathways, contrast media are integral to diagnostic accuracy, so demand is relatively inelastic to small price fluctuations — although procurement practice and tendering by hospitals, health systems, and large distributors can exert strong price pressure.

The Iohexol API market is a technically and regulatory-intensive niche within the broader contrast media and radiopharmaceutical supply chain. Its demand is underpinned by durable clinical needs — diagnostic CT and image-guided procedures — with steady growth driven by demographic changes and expanding global imaging capacity. Market developments will be shaped by: regulatory expectations (pharmacopeial alignment, DMFs), procurement behavior (tendering and generic competition), supplier capability (GMP/DMF/CEP credentials), and regional investment in imaging infrastructure. While substitution risk is limited for many CT applications, cost pressure, supply reliability, and environmental/regulatory compliance will continue to drive supplier consolidation, vertical integration, and selective capacity investments. For new entrants, the combination of capital-intensive quality systems and the need to support regulatory dossiers makes the market accessible mainly to established API manufacturers or CMOs that can rapidly meet pharmacopeial and regulatory demands.

Global key manufacturers of Iohexol API include GE Healthcare, Otsuka Chemicals, Starry, etc. Global top three manufacturers hold a share about 85%.

This report presents a comprehensive overview of the global Iohexol API market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Original Drug
• Generic Drug

Segment by Purity and Quality Grade

• Pharmaceutical Grade (GMP-Grade)
• Technical or Laboratory Grade
• Custom Purity Grades

Segment by Assay (Content of Iohexol)

• Standard Assay (≥ 99.0%)
• High Assay (≥ 99.5%)
• Research or Technical Grade (≥ 97–98%)

Segment by Application

• Hospitals
• Clinics

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Iohexol API market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospitals, Clinics evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact